Gut Microbiota and Their Metabolites in Hemodialysis Patients
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A
. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018; 33(suppl_3):iii28-iii34.
PMC: 6168816.
DOI: 10.1093/ndt/gfy174.
View
2.
Luo D, Zhao W, Lin Z, Wu J, Lin H, Li Y
. The Effects of Hemodialysis and Peritoneal Dialysis on the Gut Microbiota of End-Stage Renal Disease Patients, and the Relationship Between Gut Microbiota and Patient Prognoses. Front Cell Infect Microbiol. 2021; 11:579386.
PMC: 8021868.
DOI: 10.3389/fcimb.2021.579386.
View
3.
Wang L, Xu X, Zhang M, Hu C, Zhang X, Li C
. Prevalence of Chronic Kidney Disease in China: Results From the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Intern Med. 2023; 183(4):298-310.
PMC: 9941971.
DOI: 10.1001/jamainternmed.2022.6817.
View
4.
Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M
. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol. 2013; 24(12):1981-94.
PMC: 3839540.
DOI: 10.1681/ASN.2012030281.
View
5.
. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225):709-733.
PMC: 7049905.
DOI: 10.1016/S0140-6736(20)30045-3.
View